Search

Displaying results 8071 - 8080 of 10000 in total
  1. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  2. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient. … This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.

  3. Drug

    R-851

    go.drugbank.com/drugs/DB05747
    Experimental

    R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells.

  4. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol … LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect

  5. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  6. Drug

    Serelaxin

    go.drugbank.com/drugs/DB05794
    Investigational

    Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic … bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy.

  7. Drug

    Alethine

    go.drugbank.com/drugs/DB05800
    Investigational

    It belongs to a family of chemicals called disulfides. It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models.

  8. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.

  9. Drug

    KOS-1584

    go.drugbank.com/drugs/DB05903
    Investigational

    KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. … KOS-1584 is a second-generation compound with increased potency, favorable tissue distribution, and ease of formulation.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.